Testis

C62WHO Vol. 8

Male Reproductive System

Prognosis

This section is being prepared by our editorial process.

🔬 Histological Types

📚 Latest Research

2026-09-08

[Large-cell calcifying Sertoli cell tumor of the testis in children: a clinicopathological analysis of four cases].

Wu BY, et al

A clinicopathological analysis of four pediatric cases of large-cell calcifying Sertoli cell tumor (LCCSCT) of the testis provides detailed characterization of this rare testicular sex cord-stromal neoplasm in children. LCCSCT is distinguished by large eosinophilic cells arranged in cords or nests within a fibrous stroma containing prominent calcifications, and its recognition is clinically important because it may be associated with genetic syndromes such as Carney complex and Peutz-Jeghers syndrome. The authors describe the clinical presentations, histopathological features, immunohistochemical profiles, and outcomes of all four cases, aiming to improve diagnostic accuracy and guide management decisions for this uncommon entity. Accurate pathological diagnosis is essential to distinguish LCCSCT from other testicular tumors and to prompt appropriate genetic counseling and surveillance in affected children.

Zhonghua bing li xue za zhi = Chinese journal of pathology

Source →

2026-09-07

Contemporary Trends in Primary Retroperitoneal Lymph Node Dissection in Nonseminomatous Germ Cell Tumors.

Lee NJ, et al

A large population-based study using the SEER database (2007–2022) found that the use of primary retroperitoneal lymph node dissection (RPLND) declined dramatically in marker-negative nonseminomatous germ cell tumors (NSGCTs) of the testis across all disease stages: in stage I, utilization dropped from 16% (39 patients) in 2007 to just 2.4% (15 patients) in 2022, while in stage IIa it fell from 33% to 28% and in stage IIb from 52% to 28% over the same period. The study analyzed 6,222 stage I, 766 stage IIa, and 649 stage IIb patients, confirming that a more contemporary year of diagnosis independently predicted lower primary RPLND use across all three stages (all p < 0.05). Despite this shift away from surgery, 10-year cancer-specific mortality rates remained low and did not significantly differ between primary RPLND and chemotherapy in either stage I or stage II disease. The authors warn that the sharp decline in RPLND volume raises serious concern about the long-term ability of surgical centers to maintain the procedural expertise necessary to perform this technically demanding operation safely.

European urology focus

Source →

2026-09-07

Testicular aggressive B-cell lymphoma with plasmablastic morphology harboring concurrent IGH::MYC and IGH::BCL2 rearrangements.

Kim B, et al

Researchers report a rare case of testicular aggressive B-cell lymphoma with plasmablastic morphology harboring concurrent IGH::MYC and IGH::BCL2 rearrangements in a 66-year-old immunocompetent man who presented with a 5 cm left testicular mass. Fluorescence in situ hybridization detected the IGH::MYC [t(8;14)] rearrangement in 45% and the IGH::BCL2 [t(14;18)] rearrangement in 21% of analyzed nuclei, while next-generation sequencing additionally uncovered a BRAF V600E mutation, CDKN2A deletion, and human leukocyte antigen class I genomic alterations. The tumor expressed CD138, CD38, and MUM1 but lacked canonical B-cell markers such as CD20, CD19, and PAX5, placing it at a diagnostically challenging interface between plasmablastic lymphoma and double-hit lymphoma. This case underscores the critical value of integrated morphologic, immunophenotypic, cytogenetic, and molecular evaluation when characterizing aggressive B-cell lymphomas with plasmablastic features arising in immune-privileged sites such as the testis.

Journal of hematopathology

Source →